Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the checkpoint kinase WEE1: selective sensitization of cancer cells to DNA-damaging drugs.

× No keyword cloud information.

13 in total

Review 1. DNA damage response pathways and cell cycle checkpoints in colorectal cancer: current concepts and future perspectives for targeted treatment.

Authors: S Solier; Y-W Zhang; A Ballestrero; Y Pommier; G Zoppoli
Journal: Curr Cancer Drug Targets Date: 2012-05 Impact factor: 3.428

2. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells.

Authors: Jenny M Kreahling; Jennifer Y Gemmer; Damon Reed; Douglas Letson; Marilyn Bui; Soner Altiok
Journal: Mol Cancer Ther Date: 2011-11-14 Impact factor: 6.261

3. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia.

Authors: Tamara B Garcia; Jonathan C Snedeker; Dmitry Baturin; Lori Gardner; Susan P Fosmire; Chengjing Zhou; Craig T Jordan; Sujatha Venkataraman; Rajeev Vibhakar; Christopher C Porter
Journal: Mol Cancer Ther Date: 2017-06-27 Impact factor: 6.261

4. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells.

Authors: Kathleen A Bridges; Hiroshi Hirai; Carolyn A Buser; Colin Brooks; Huifeng Liu; Thomas A Buchholz; Jessica M Molkentine; Kathryn A Mason; Raymond E Meyn
Journal: Clin Cancer Res Date: 2011-07-28 Impact factor: 12.531

5. Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma.

Authors: Zejia Yang; Jipei Liao; Rena G Lapidus; Xiaoxuan Fan; Ranee Mehra; Kevin J Cullen; Hancai Dan
Journal: Cancer Chemother Pharmacol Date: 2022-02-25 Impact factor: 3.333

6. Abrogating G₂/M checkpoint through WEE1 inhibition in combination with chemotherapy as a promising therapeutic approach for mesothelioma.

Authors: Paola Indovina; Eleonora Marcelli; Domenico Di Marzo; Nadia Casini; Iris Maria Forte; Francesca Giorgi; Luigi Alfano; Francesca Pentimalli; Antonio Giordano
Journal: Cancer Biol Ther Date: 2014-01-14 Impact factor: 4.742

7. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.

Authors: C C Porter; J Kim; S Fosmire; C M Gearheart; A van Linden; D Baturin; V Zaberezhnyy; P R Patel; D Gao; A C Tan; J DeGregori
Journal: Leukemia Date: 2012-01-13 Impact factor: 11.528

8. Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner.

Authors: Jiajie Guo; Guosheng Wu; Jiaolin Bao; Wenhui Hao; Jinjian Lu; Xiuping Chen
Journal: PLoS One Date: 2014-02-04 Impact factor: 3.240

9. Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells---Cdc2 activity is up-regulated by targeting WEE1.

Authors: Binghai Chen; Lujing Duan; Guangming Yin; Jing Tan; Xianzhen Jiang
Journal: Clinics (Sao Paulo) Date: 2013-06 Impact factor: 2.365

10. Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.

Authors: Jenny M Kreahling; Parastou Foroutan; Damon Reed; Gary Martinez; Tiffany Razabdouski; Marilyn M Bui; Meera Raghavan; Douglas Letson; Robert J Gillies; Soner Altiok
Journal: PLoS One Date: 2013-03-08 Impact factor: 3.240